Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vanda Pharmaceuticals (VNDA)
:VNDA
Holding VNDA?
Track your performance easily
VNDA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.46 - $6.75
Previous CloseN/A
Volume240.10K
Average Volume (3M)617.80K
Market Cap
$258.89M
Enterprise Value-$95.07M
Total Cash (Recent Filing)$141.34M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Feb 05, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding58,308,144
10 Day Avg. Volume502,911
30 Day Avg. Volume617,798
Standard Deviation0.12
R-Squared0.10
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.36
Price to Cash Flow (P/CF)-4.40
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.37
Enterprise Value/Revenue-0.50
Enterprise Value/Gross Profit-0.53
Enterprise Value/Ebitda5.87
Forecast
1Y Price Target
$15.50Price Target Upside249.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Vanda News
PremiumCompany Announcements
Vanda Pharmaceuticals Reports Strong Q3 2024 Growth
Bulls Say, Bears Say
Bulls Say
Market ResponseSeveral lead indicators suggest a strong initial market response to Fanapt for acute treatment of bipolar I disorder in adults, including new patient starts as reflected by new to brand prescriptions (NBRx), increasing by over 90% in 3Q24 compared to 3Q23.
Product DevelopmentMultiple upcoming inflection points, including the initiation of the pivotal iloperidone long-acting injectable clinical program and submission of the New Drug Application for milsaperidone in schizophrenia and bipolar I disorder, are expected to drive value for Vanda.
Regulatory ApprovalThe FDA has granted Orphan Drug Designation for VGT-1849A, a selective antisense oligonucleotide-based JAK2 inhibitor for the treatment of polycythemia vera, providing potential market exclusivity and benefits.
Bears Say
EarningsPonvory net sales were $5.9M in 3Q24, a decrease of 32% vs. $8.6M in 2Q24.
Product CompetitionThe ongoing genericization of Vanda's sleep disorders franchise has obscured the investment community's sight of Vanda's underlying value proposition.
Regulatory ChallengesThe recent receipt of a Complete Response Letter for tradipitant in gastroparesis has obscured the investment community's sight of Vanda's underlying value proposition.
---
Ownership Overview
5.30% Insiders
17.49% Mutual Funds
0.57% Other Institutional Investors
62.58% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VNDA FAQ
What was Vanda Pharmaceuticals’s price range in the past 12 months?
Vanda Pharmaceuticals lowest stock price was $3.46 and its highest was $6.75 in the past 12 months.
What is Vanda Pharmaceuticals’s market cap?
Vanda Pharmaceuticals’s market cap is $258.89M.
When is Vanda Pharmaceuticals’s upcoming earnings report date?
Vanda Pharmaceuticals’s upcoming earnings report date is Feb 05, 2025 which is in 18 days.
How were Vanda Pharmaceuticals’s earnings last quarter?
Vanda Pharmaceuticals released its earnings results on Nov 06, 2024. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.157 by $0.067.
Is Vanda Pharmaceuticals overvalued?
According to Wall Street analysts Vanda Pharmaceuticals’s price is currently Undervalued.
Does Vanda Pharmaceuticals pay dividends?
Vanda Pharmaceuticals does not currently pay dividends.
What is Vanda Pharmaceuticals’s EPS estimate?
Vanda Pharmaceuticals’s EPS estimate is -0.11.
How many shares outstanding does Vanda Pharmaceuticals have?
Vanda Pharmaceuticals has 58,308,144 shares outstanding.
What happened to Vanda Pharmaceuticals’s price movement after its last earnings report?
Vanda Pharmaceuticals reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.157. Following the earnings report the stock price went up 2.658%.
Which hedge fund is a major shareholder of Vanda Pharmaceuticals?
Currently, no hedge funds are holding shares in VNDA
---
Vanda Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.50 (249.10% Upside)
$15.50 (249.10% Upside)
Blogger Sentiment
Bullish
VNDA Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 27.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $25.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
15.95%
12-Months-Change
Fundamentals
Return on Equity
-3.02%
Trailing 12-Months
Asset Growth
0.55%
Trailing 12-Months
Company Description
Vanda Pharmaceuticals
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
---
VNDA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a strong performance for Fanapt and successful integration of PONVORY, with promising pipeline developments. However, challenges such as the decline in HETLIOZ revenue, FDA denial for tradipitant, and PONVORY sales decrease were notable setbacks.Read More>---
VNDA Stock 12 Month Forecast
Average Price Target
$15.50
▲(249.10% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Arcutis Biotherapeutics
―
Amneal Pharmaceuticals
―
Supernus Pharmaceuticals
―
Karyopharm Therapeutics
―
Xenon
―
Best Analysts Covering VNDA
1 Year
1 Year Success Rate
1/6 ratings generated profit
1 Year Average Return
-15.72%
reiterated a buy rating 2 months ago
Copying Charles Duncan's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -15.72% per trade.
---